{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mycophenolate+mofetil+%2B+Tacrolimus&page=3",
    "query": {
      "intervention": "Mycophenolate mofetil + Tacrolimus",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 347,
    "total_pages": 35,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mycophenolate+mofetil+%2B+Tacrolimus&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mycophenolate+mofetil+%2B+Tacrolimus&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-03T01:27:36.922Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02096107",
      "title": "Novartis Everolimus Transition",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Graft Dysfunction",
        "Interstitial Fibrosis"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2014-02",
      "completion_date": "2017-05",
      "has_results": true,
      "last_update_posted_date": "2018-08-08",
      "last_synced_at": "2026-10-03T01:27:36.922Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02096107"
    },
    {
      "nct_id": "NCT01008462",
      "title": "Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B-Cell Prolymphocytic Leukemia",
        "Hypodiploidy",
        "Loss of Chromosome 17p",
        "Plasma Cell Leukemia",
        "Progression of Multiple Myeloma or Plasma Cell Leukemia",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Non-Hodgkin Lymphoma",
        "Recurrent Childhood Hodgkin Lymphoma",
        "Recurrent Childhood Non-Hodgkin Lymphoma",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Plasma Cell Myeloma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Childhood Hodgkin Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Plasma Cell Myeloma",
        "Refractory Small Lymphocytic Lymphoma",
        "t(14;16)",
        "t(4;14)",
        "T-Cell Prolymphocytic Leukemia",
        "Waldenstrom Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Allogeneic Bone Marrow Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 16,
      "start_date": "2010-03-18",
      "completion_date": "2018-06-30",
      "has_results": true,
      "last_update_posted_date": "2019-06-11",
      "last_synced_at": "2026-10-03T01:27:36.922Z",
      "location_count": 2,
      "location_summary": "Seattle, Washington • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01008462"
    },
    {
      "nct_id": "NCT02921789",
      "title": "Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplantation",
        "Primary Focal Segmental Glomerulosclerosis (FSGS)"
      ],
      "interventions": [
        {
          "name": "Bleselumab",
          "type": "DRUG"
        },
        {
          "name": "Basiliximab",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus Capsules",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2017-05-22",
      "completion_date": "2021-05-18",
      "has_results": true,
      "last_update_posted_date": "2024-12-04",
      "last_synced_at": "2026-10-03T01:27:36.922Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • Palo Alto, California • San Francisco, California + 17 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02921789"
    },
    {
      "nct_id": "NCT00970073",
      "title": "Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Liver Transplantation"
      ],
      "interventions": [
        {
          "name": "Thymoglobulin 3mg total",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Thymoglobulin 4.5mg total",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus 3-8",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus 8-12",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2009-08",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2018-10-09",
      "last_synced_at": "2026-10-03T01:27:36.922Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00970073"
    },
    {
      "nct_id": "NCT01350245",
      "title": "Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndromes",
        "Biphenotypic Leukemia",
        "Acute Lymphocytic Leukemia",
        "Chronic Myeloid Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Plasma Cell Neoplasms",
        "Lymphoma",
        "Hodgkin's Disease",
        "Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "Total Body Irradiation (TBI)",
          "type": "RADIATION"
        },
        {
          "name": "Donor Lymphocyte Infusion (DLI)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Hematopoietic stem cell transplantation (HSCT)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "BIOLOGICAL",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2010-07",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-10-03T01:27:36.922Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01350245"
    },
    {
      "nct_id": "NCT07349771",
      "title": "Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic and Lymphatic System Neoplasm"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Axatilimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Skin Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2026-06-01",
      "completion_date": "2033-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-03T01:27:36.922Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07349771"
    },
    {
      "nct_id": "NCT00709592",
      "title": "Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma",
        "Leukemia",
        "Multiple Myeloma",
        "Acute Myeloid Leukemia",
        "Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Chronic Myelogenous Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Thymoglobulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Allogeneic PBSCT or BMT",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 42,
      "start_date": "2008-07-21",
      "completion_date": "2017-06-28",
      "has_results": true,
      "last_update_posted_date": "2018-11-09",
      "last_synced_at": "2026-10-03T01:27:36.922Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00709592"
    },
    {
      "nct_id": "NCT00619216",
      "title": "Myfortic Conversion Trial in OLT Recipients With GI Intolerance",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "GI Disturbance"
      ],
      "interventions": [
        {
          "name": "Mycophenolic Acid (Myfortic)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 31,
      "start_date": "2008-03",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2011-06-03",
      "last_synced_at": "2026-10-03T01:27:36.922Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00619216"
    },
    {
      "nct_id": "NCT01544491",
      "title": "Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant"
      ],
      "interventions": [
        {
          "name": "RAD001",
          "type": "DRUG"
        },
        {
          "name": "MMF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Year to 18 Years"
      },
      "enrollment_count": 106,
      "start_date": "2012-08-17",
      "completion_date": "2018-09-24",
      "has_results": true,
      "last_update_posted_date": "2019-05-31",
      "last_synced_at": "2026-10-03T01:27:36.922Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01544491"
    },
    {
      "nct_id": "NCT04903054",
      "title": "Selective CD28 Blockade in Renal Transplant Recipients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplantation",
        "Renal Transplant Recipients"
      ],
      "interventions": [
        {
          "name": "Lulizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Thymoglobulin®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-01-10",
      "completion_date": "2022-09-22",
      "has_results": false,
      "last_update_posted_date": "2023-03-22",
      "last_synced_at": "2026-10-03T01:27:36.922Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04903054"
    }
  ]
}